Relator Leslie Steury, on behalf of the United States, claims that defendants Cardinal Health, Inc., Cardinal Health 303 Inc., and Cardinal Health Solutions, Inc., successors to Alaris Medical Systems, Inc., sold the United States Department of Veterans Affairs defective medical equipment in violation of the False Claims Act (FCA), 31 U.S.C. § 3729(a) (2009). A magistrate judge recommended dismissing Steury’s complaint for failure to state a claim under Federal Rules of Civil Procedure 9(b) and 12(b)(6), but also recommended granting Steury leave to amend. Both parties filed timely objections. After de novo review, the district court adopted the magistrate judge’s recommendations in full. The same day, the district court entered a final judgment dismissing Steury’s action. *265 Steury appeals on grounds that she stated a claim under Rules 9(b) and 12(b)(6), and alternatively that the district court abused its discretion in denying her an opportunity to amend her complaint. We affirm the district court’s decision with respect to Steury’s failure to state a claim, but we vacate the final judgment and remand to give Steury an opportunity to amend.
I. BACKGROUND
According to her amended complaint, Steury marketed Cardinal’s Signature Edition Infusion Device (Signature pump) to various hospitals, including hospitals operated by the Veterans Administration, from March 18, 1996 until her termination on September 28, 2001. The Signature pump is an electronic device that regulates the rate at which intravenous fluids flow into patients. Steury alleges that the Signature pump has a dangerous defect that can cause air bubbles to accumulate and ultimately release into a patient’s intravenous line, potentially resulting in serious injury or death. Steury alleges that Cardinal sold Signature pumps to the Veterans Administration from 1997 until August 26, 2006, at which time Cardinal suspended production, sales, repairs, and installation of the Signature pump after certain devices were recalled by the Food and Drug Administration for a separate problem.
Steury alleges that she first became aware of the air-in-line defect in the Signature pump in October 2000. Steury asserts that Dr. Mark DiLuciano, a pediatric anesthesiologist at Children’s Hospital of Akron, informed Susan Springman, another Alaris employee, that a Signature pump had injected air into his patient’s intravenous line, and that a similar problem had been reported at Children’s Hospital of Philadelphia. On May 23, 2001, Steury allegedly met with John Snow (Alaris’s area manager) and nurses from Children’s Hospital of Akron to discuss concerns about the Signature pump. According to Steury, Snow discredited a nurse’s report of an infant mortality related to an intravenous air bubble. Steury asserts that she and various other Alaris employees again discussed the air-in-line defect during a conference call on May 25, 2001 and at a meeting on May 31, 2001.
In June 2001, Snow allegedly informed Steury that Alaris had temporarily suspended shipments of Signature pumps while it reviewed the air-in-line defect, but nonetheless directed Steury to continue marketing the Signature pump. Steury asserts that she was told to expect a final answer from Snow within 90 days. Emails attached to Steury’s complaint suggest that Children’s Hospital of Akron continued to raise concerns about the Signature pump between June and September 2001. On September 28, 2001, Alaris terminated Steury’s employment. According to Steury, she would have “completed filling a major order” of Signature pumps by the Veterans Administration Hospital of Ohio only five days later.
Steury sued Cardinal on May 11, 2007 for alleged violations of the FCA and a number of similar state statutes. The United States filed a notice of declination to intervene pursuant to 31 U.S.C. § 3730(b)(4)(B) on January 28, 2008. On November 26, before Cardinal answered, Steury filed an amended complaint. The amended complaint again raised claims under the FCA and similar state statutes. In addition to the above factual allegations, Steury’s amended complaint asserts, in relevant part:
51____ A claimant submits a false or fraudulent claim within the meaning of the FCA when he submits a claim for payment to the Government for products that contain defective parts.
*266 52. By accepting payment from the federal Government or one of its agencies for the SE infusion pumps, Cardinal Health knowingly misrepresented that the SE infusion pumps were safe, reliable, and quality-assured.
54. A false certification occurs when the Government has conditioned payment of a claim upon the certification of compliance with, for example, a contract provision, regulation or statute. The claimant submits a false or fraudulent claim within the meaning of the FCA when he or she falsely certifies compliance with that contract provision or statute. These certifications can either be express or implied.
58. An implied false certification theory occurs when a claimant submits a false claim without expressly certifying compliance with a contract provision, statute, regulation, or governmental program. Liability is imposed on the premise of breach of contract or an implied responsibility, not a financial loss.
59. Cardinal Health is obligated to provide safe, reliable, and quality-tested products, which perform to their specifications, to the Government. By delivering and receiving payments for the SE infusion pumps, Cardinal Health is impliedly certifying compliance with the terms of its contract with the Government for the products.
Cardinal moved to dismiss Steury’s complaint on February 2, 2009, and the matter was referred to a magistrate judge. On August 31, 2009, the magistrate judge issued a report and recommendation finding, inter alia, that Steury’s allegations of fraud did not satisfy the heightened pleading requirements of Rule 9(b) and thus failed to state a claim under Rule 12(b)(6). The magistrate judge recommended that Steury’s “complaint be dismissed without prejudice to the filing of an amended complaint within ten days, if this recommendation is adopted.” Both parties filed timely objections. On September 25, 2009, after de novo review, the district court adopted the magistrate judge’s report and recommendation in full. On the same day, the district court entered a final judgment dismissing Steury’s “action.” In bold letters, the district court confirmed that “THIS IS A FINAL JUDGMENT.” Steury filed a timely notice of appeal on October 23, 2009.
II. STANDARD OF REVIEW
We review de novo a district court’s ruling on a Rule 12(b)(6) motion.
United States ex rel. Willard v. Humana Health Plan of Tex. Inc.,
We review a district court’s denial of leave to amend a pleading for abuse of discretion.
See Del Prado v. B.N. Dev. Co.,
*267 III. DISCUSSION
Steury has expressly limited the issues on appeal to: (1) whether Steury stated a claim under the FCA “when she alleged that the defendant sold the Veterans Administration medical equipment that it knew was defective and unsafe”; and if not, (2) whether the district court erred in granting final judgment without allowing her an opportunity to amend her complaint.
A. Failure To State A Claim
The FCA is the Government’s “primary litigation tool” for recovering losses resulting from fraud.
Marcy,
In an effort to “streamline” this appeal, Steury presses only one substantive contention: that Cardinal made a false certification (i.e., a false statement) to the Veterans Administration that the Signature pumps complied with the warranty of merchantability.
2
Steury does not assert that
*268
Cardinal actually (i.e., expressly) made this certification.
See Thompson,
The implied-certification theory of liability under the FCA “is based on the notion that the act of submitting a claim for reimbursement itself implies compliance with governing federal rules that are a precondition to payment.”
Mikes v. Straus,
The FCA is not a general “enforcement device” for federal statutes, regulations, and contracts.
Thompson,
Courts have at times located the prerequisite requirement in the materiality prong of FCA analysis.
See, e.g., Marcy,
In this case, we find no indication that the Government conditioned payment for the Signature pumps on a certification that the Signature pumps complied with the warranty of merchantability. Steury does not allege that the particular contracts between Cardinal and the Government impose a warranty of merchantability. Steury instead draws our attention to certain Federal Acquisition Regulations (FAR),
see
48 C.F.R. § 12.404(a), but the regulations do not sustain her claim. Section 12.404(a) explains that the standard warranty clause in federal commercial acquisition contracts,
see id.
§ 52.212-4(o), includes a warranty of merchantability and a warranty of fitness for a particular purpose.
Id.
§ 12.404(a). The warranties may be excluded or limited, however, by express warranty.
Id.
§ 12.404(b)(2);
see also id.
§ 12.302(a) (recognizing that clauses in § 52.212-4 may be “tailor[ed] ... to adapt to the market conditions for each acquisition”). Thus, Cardinal is not even necessarily subject to an implied warranty of merchantability under the FAR. Moreover, the FAR expressly condition payment for commercial items on
acceptance
(as opposed to compliance with the warranty of merchantability),
see id.
§ 52.212-4(i) (providing that “payment shall be made for items accepted by the Government .... ”), and the FAR also permit the Government to seek a range of remedies in the event it receives noncompliant items from a contractor, including acceptance, price reduction or replacement.
See id.
*270
§§ 46.407(b)-(d), (f), 52.246-2(k), (Z). As we have recognized on previous occasions, the Government’s ability to seek a range of remedies in the event of noncompliance suggests that payment is not conditioned on a certification of compliance.
See Willard,
To conclude, we hold that Cardinal did not make an implied certification that the Signature pumps complied with the warranty of merchantability simply because the Government’s standard commercial-acquisition contract includes a warranty of merchantability. We do not suggest, however, that a knowing delivery of defective goods to the Government will never implicate the FCA. Particular government contracts may specifically condition payment on a certification of compliance with the warranty of merchantability. Other courts have suggested that the knowing provision of “worthless” goods or services to the Government may violate the FCA.
See, e.g., Mikes,
B. Amendment
A district court should “freely give leave” to amend a complaint “when justice so requires.” Fed.R.Civ.P. 15(a)(2). Denial of leave to amend may be warranted for undue delay, bad faith or dilatory motive on the part of the movant, repeated failure to cure deficiencies, undue prejudice to the opposing party, or futility of a proposed amendment.
See Rosenblatt v. United Way of Greater Houston,
In this case, the district court
granted
Steury leave to amend her complaint but nonetheless entered a final judgment before her time to amend expired (or even began for that matter). The district court’s entry of final judgment may have been intentional or it may have been a mistake; either way, it was an abuse of discretion to reverse course without providing any reason whatever. It is true that Steury has already amended her complaint once, but this was done shortly after Cardinal was served and before Cardinal filed an answer. It does not appear that Steury has unduly delayed this action, or that she is pursuing it in bad faith. Cardinal has not shown that it would suffer undue prejudice if Steury were permitted to amend her complaint, and we cannot say that the defects in Steury’s complaint are necessarily “incurable” or that amendment would be futile.
See Great Plains Trust Co. v. Morgan Stanley Dean Witter & Co.,
AFFIRMED IN PART, VACATED IN PART, AND REMANDED.
Notes
. Although the 2009 amendments to the FCA generally apply only to conduct on or after May 20, 2009, § 3729(a)(1)(B) applies retroactively to all claims pending on or after June 7, 2008 (that is, just before the Supreme Court’s decision in
Allison Engine Co. v. United States ex rel. Sanders,
. Steury has not briefed, and indeed has expressly disclaimed, other challenges to the district court’s decision. Steury therefore has waived other potential challenges.
See, e.g.,
Fed. R.App. P. 28(a)(9)(A) (requiring appellant’s brief to include appellant’s contentions
*268
and the reasons for them);
Procter & Gamble Co. v. Amway Corp.,
. Cardinal asserts that Steury did not base her implied-certification theory of liability specifically on the warranty of merchantability before the district court. We recognize the fundamental principle that a plaintiff may not raise an entirely new issue for the first time on appeal,
see, e.g., Martinez v. Tex. Dep’t of Criminal Justice,
. As we have recognized in the past, whether payment is conditioned on compliance will depend on the specific statutes, regulations, and contracts at issue in a particular case.
See Thompson,
